Streamline Surgical System combined with phacoemulsification, transluminal dilation significantly reduces IOP

The Streamline Surgical System can effectively lower intraocular pressure (IOP) in eyes undergoing combined phacoemulsification and transluminal dilation for open-angle glaucoma (OAG), according to a study presented at the ASCRS Annual Meeting 2023.

The study included 20 eyes of 20 subjects with OAG who underwent IOP measurement and medication count at the screening visit and at an eligibility visit post-medication washout. Data were collected at various time points including postoperative day 1; week 1; and at 1, 3, and 6 months.

The results of the study showed that the mean IOP at the screening visit was 17.0 (3.8) mmHg and rose to 22.8 (2.1) mmHg after washout. However, postoperative mean IOP was significantly lower than unmedicated IOP at all time points. The reduction in IOP ranged from 5.5-9.5 mmHg (23.9-41.6%). The mean IOP reduction at 3 and 6 months, respectively, were -8.85 and -9.53mmHg from unmedicated baseline. The mean screening medication use was 1.8 medications and all eyes remained completely medication-free throughout follow-up (P < 0.0001 at all-time points).

The study concluded that in eyes with coexistent cataract and OAG, combined phacoemulsification and transluminal dilation with the Streamline Surgical System provides significant reduction in both IOP and IOP-lowering medications through the first 6 postoperative months. However, 1 eye did develop corneal ulceration related to foreign body postoperatively, unrelated to the Streamline Surgical System transluminal dilation.

Reference
Orlich C, et al. Early Clinical Outcomes of Combined Phacoemulsification and Streamline™ Surgical System Transluminal Dilation. Presented at: ASCRS Annual Meeting 2023.